{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:18:01Z","timestamp":1789039081163,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004315","name":"GlaxoSmithKline USA Rockville","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.vaccine.2023.05.025","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T12:49:41Z","timestamp":1686833381000},"page":"4347-4358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review"],"prefix":"10.1016","volume":"41","author":[{"given":"Elisa","family":"Cinconze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Rosillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kumaran","family":"Vadivelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Bekkat-Berkani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1987-363X","authenticated-orcid":false,"given":"Victoria","family":"Abbing-Karahagopian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.05.025_b0005","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/oxfordjournals.aje.a009196","article-title":"Study designs for evaluating different efficacy and effectiveness aspects of vaccines","volume":"146","author":"Halloran","year":"1997","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0010","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jclinepi.2010.07.017","article-title":"GRADE guidelines: 4. Rating the quality of evidence\u2013study limitations (risk of bias)","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1503\/cmaj.120592","article-title":"Adjustment for continuous confounders: An example of how to prevent residual confounding","volume":"185","author":"Groenwold","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.vaccine.2023.05.025_b0020","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. Chichester (UK): John Wiley & Sons; 2008."},{"key":"10.1016\/j.vaccine.2023.05.025_b0025","doi-asserted-by":"crossref","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142. https:\/\/doi.org\/10.1002\/14651858.ED000142.","DOI":"10.1002\/14651858.ED000142"},{"key":"10.1016\/j.vaccine.2023.05.025_b0030","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006-12. https:\/\/doi.org\/10.1016\/j.jclinepi.2009.06.005.","DOI":"10.1016\/j.jclinepi.2009.06.005"},{"key":"10.1016\/j.vaccine.2023.05.025_b0035","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/EDE.0b013e3181577511","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"18","author":"Vandenbroucke","year":"2007","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2023.05.025_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.05.025_b0045","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.05.025_b0050","doi-asserted-by":"crossref","first-page":"ofy292","DOI":"10.1093\/ofid\/ofy292","article-title":"Effectiveness of the Oral Human Attenuated Rotavirus Vaccine: A Systematic Review and Meta-analysis-2006-2016","volume":"5","author":"Willame","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.025_b0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5501\/wjv.v10.i4.182","article-title":"Current systematic reviews and meta-analyses of COVID-19","volume":"10","author":"Nassar","year":"2021","journal-title":"World J Virol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0060","article-title":"Framework for the synthesis of non-randomised studies and randomised controlled trials: a guidance on conducting a systematic review and meta-analysis for healthcare decision making","author":"Sarri","year":"2020","journal-title":"BMJ Evid Based Med"},{"key":"10.1016\/j.vaccine.2023.05.025_b0065","article-title":"How well can we assess the validity of non-randomised studies of medications? A systematic review of assessment tools","volume":"11","author":"D\u2019Andrea","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2023.05.025_b0070","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41541-021-00388-3","article-title":"Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect","volume":"6","author":"Ruiz Garcia","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.vaccine.2023.05.025_b0075","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases, https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-i-vaccines_en.pdf; 2013 [accessed 15 June 2022]."},{"key":"10.1016\/j.vaccine.2023.05.025_b0080","unstructured":"U.S. Food and Drug Administration. Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines, https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines; 2001 [accessed 22 September 2021]."},{"key":"10.1016\/j.vaccine.2023.05.025_b0085","unstructured":"World Health Organization. Overview of Vaccine Preventable Diseases Surveillance Principles, https:\/\/www.who.int\/docs\/default-source\/immunization\/vpd_surveillance\/vpd-surveillance-standards-publication\/who-surveillancevaccinepreventable-01-overview-r2.pdf?sfvrsn=932d9e08_8; 2018 [accessed 15 June 2022]."},{"key":"10.1016\/j.vaccine.2023.05.025_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jinf.2021.04.031","article-title":"Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination","volume":"83","author":"Martinon-Torres","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.05.025_b0095","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1093\/cid\/ciaa1733","article-title":"Effectiveness of meningococcal vaccines at reducing invasive meningococcal disease and pharyngeal Neisseria meningitidis carriage: A systematic review and meta-analysis","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.025_b0100","first-page":"8","article-title":"Effectiveness and Impact of the 4CMenB Vaccine against Group B Meningococcal Disease in Two Italian Regions Using Different Vaccination Schedules: A Five-Year Retrospective Observational Study (2014\u20132018)","author":"Azzari","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2023.05.025_b0105","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1016\/j.vaccine.2019.06.021","article-title":"Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch","volume":"37","author":"Deceuninck","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.025_b0110","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1901229","article-title":"Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England","volume":"382","author":"Ladhani","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.025_b0115","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1093\/cid\/ciaa1636","article-title":"Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents","volume":"73","author":"McMillan","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.025_b0120","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1001\/jama.2020.20449","article-title":"Association of Use of a Meningococcus Group B Vaccine With Group B Invasive Meningococcal Disease Among Children in Portugal","volume":"324","author":"Rodrigues","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2023.05.025_b0125","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/cix154","article-title":"Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada","volume":"64","author":"De Wals","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.05.025_b0130","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/S0140-6736(16)31921-3","article-title":"Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study","volume":"388","author":"Parikh","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2023.05.025_b0135","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ije\/22.4.742","article-title":"Estimation of vaccine effectiveness using the screening method","volume":"22","author":"Farrington","year":"1993","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0140","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1056\/NEJMoa1900236","article-title":"Meningococcal B Vaccine and Meningococcal Carriage in Adolescents in Australia","volume":"382","author":"Marshall","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.05.025_b0145","unstructured":"Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell T. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp; 2021 [accessed 15 June 2022]."},{"key":"10.1016\/j.vaccine.2023.05.025_b0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0155","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2020.12.017","article-title":"A modified Newcastle-Ottawa scale for assessment of study quality in genetic urological research","volume":"79","author":"Norris","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0160","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/ije\/dym018","article-title":"Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography","volume":"36","author":"Sanderson","year":"2007","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0165","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.05.025_b0170","doi-asserted-by":"crossref","first-page":"6455","DOI":"10.1016\/j.vaccine.2008.06.041","article-title":"Essential tools for assessing influenza vaccine efficacy in improperly conducted studies: a Japanese perspective","volume":"26","author":"Hirota","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.05.025_b0175","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/clpt.2011.199","article-title":"Registration of observational studies does not enhance validity","volume":"90","author":"Savitz","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vaccine.2023.05.025_b0180","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2023.05.025_b0185","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jclinepi.2011.01.011","article-title":"GRADE guidelines: 5. Rating the quality of evidence\u2013publication bias","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0190","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.jclinepi.2011.06.004","article-title":"GRADE guidelines: 9. Rating up the quality of evidence","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2023.05.025_b0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d549","article-title":"Interpretation of random effects meta-analyses","volume":"342","author":"Riley","year":"2011","journal-title":"BMJ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23005522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23005522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:47Z","timestamp":1759404467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23005522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":39,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0264410X23005522"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Challenges in synthesis of real-world vaccine effects on meningococcal serogroup B disease for 4CMenB vaccine post-licensure effectiveness studies: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.05.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 GSK. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}